Multiple Myeloma Cells Recruit Tumor-supportive Macrophages Through the CXCR4/CXCL12 Axis and Promote Their Polarization Toward the M2 Phenotype
Overview
Authors
Affiliations
Multiple myeloma (MM) cells specifically attract peripheral-blood monocytes, while interaction of MM with bone marrow stromal cells (BMSCs) significantly increased monocyte recruitment (p<0.01). The CXCL12 chemokine, produced by both the MM and BMSCs, was found to be a critical regulator of monocyte migration. CXCL12 production was up-regulated under MM-BMSCs co-culture conditions, whereas blockage with anti-CXCR4 antibodies significantly abrogated monocyte recruitment toward a MM-derived conditioned medium (p<0.01). Furthermore, elevated levels of CXCL12 were detected in MM, but not in normal BM samples, whereas malignant MM cells often represented the source of increased CXCL12 in the BM. Blood-derived macrophages effectively supported MM cells proliferation and protected them from chemotherapy-induced apoptosis. Importantly, MM cells affected macrophage polarization, elevating the expression of M2-related scavenger receptor CD206 in macrophages and blocking LPS-induced TNFα secretion (a hallmark of M1 response). Of note, MM-educated macrophages suppressed T-cell proliferation and IFNγ production in response to activation. Finally, increased numbers of CXCR4-expressing CD163+CD206+ macrophages were detected in the BM of MM patients (n=25) in comparison to MGUS (n=11) and normal specimens (n=8). Taken together, these results identify macrophages as important players in MM tumorogenicity, and recognize the CXCR4/CXCL12 axis as a critical regulator of MM-stroma interactions and microenvironment formation.
A comprehensive analysis of molecular characteristics of hot and cold tumor of gastric cancer.
Lv C, Chen T, Li J, Shan Y, Zhou H Cancer Immunol Immunother. 2025; 74(3):102.
PMID: 39904894 PMC: 11794920. DOI: 10.1007/s00262-025-03954-z.
New horizons in our understanding of precursor multiple myeloma and early interception.
Cordas Dos Santos D, Toenges R, Bertamini L, Alberge J, Ghobrial I Nat Rev Cancer. 2024; 24(12):867-886.
PMID: 39414947 DOI: 10.1038/s41568-024-00755-x.
Daccache J, Park E, Junejo M, Abdelghaffar M, Hwang E, Mohanty C J Allergy Clin Immunol. 2024; 154(5):1216-1231.
PMID: 39098508 PMC: 11560686. DOI: 10.1016/j.jaci.2024.07.021.
Lu K, Wang W, Liu Y, Xie C, Liu J, Xing L Front Oncol. 2024; 14:1413494.
PMID: 39087026 PMC: 11288838. DOI: 10.3389/fonc.2024.1413494.
Li Z, Duan D, Li L, Peng D, Ming Y, Ni R Front Pharmacol. 2024; 15:1382256.
PMID: 38957393 PMC: 11217528. DOI: 10.3389/fphar.2024.1382256.